GlaxoSmithKline

Blue chips jump 1.6%

Scott McKenzie, investment director and manager of the Saracen UK Income fund, says the largest dividend payers in the UK market currently offer limited potential for growth, particularly as the strong dollar is masking inherent weaknesses in many business...

Mark Barnett has told Investment Week he is "concerned" over the fortunes of GlaxoSmithKline, a core holding in the Invesco Perpetual Income funds which he began running at the start of March 2014.

Threadneedle's Richard Colwell is adding more to stocks including Centrica and GlaxoSmithKline as he seeks contrarian equity income plays for the months ahead.

As people live longer than ever before and traditional sources of income fail to yield enough for lengthy retirement periods, choosing the correct income source is becoming essential.

Managing the low inflation challenge

SWMC European Fund manager Stuart Mitchell has taken a stake in GlaxoSmithKline following 'years' of pronounced share price underperformance from the pharma giant.

Nick Kirrage has begun adding supermarkets to the £1.5bn Schroder Income fund he co-manages with Kevin Murphy, expecting a significant boost to dividends in the long term.

MFM Slater Income

Other large caps may follow Tesco in cutting dividends